-

AbCellera to Report Full Year 2025 Financial Results on February 24, 2026

VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) will announce its full year 2025 financial results on Tuesday, February 24, 2026, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.

A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera’s Investor Relations website. A replay will be available through the same link following the conference call.

About AbCellera Biologics Inc.

AbCellera (Nasdaq: ABCL) is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines in the areas of endocrinology, women’s health, immunology, and oncology. For more information, please visit www.abcellera.com.

Contacts

Inquiries
Media: Tiffany Chiu; media@abcellera.com, +1(236)521-6774
Partnering: Murray McCutcheon, Ph.D.; partnering@abcellera.com, +1(604)559-9005
Investor Relations: Peter Ahn; ir@abcellera.com, +1(778)729-9116

Industry:

AbCellera Biologics Inc.

NASDAQ:ABCL
Release Summary
AbCellera to Report Full Year 2025 Financial Results on February 24, 2026
Release Versions
English
$Cashtags
$ABCL

Contacts

Inquiries
Media: Tiffany Chiu; media@abcellera.com, +1(236)521-6774
Partnering: Murray McCutcheon, Ph.D.; partnering@abcellera.com, +1(604)559-9005
Investor Relations: Peter Ahn; ir@abcellera.com, +1(778)729-9116

Social Media Profiles
AbCellera on LinkedIn
AbCellera on Twitter
More News From AbCellera Biologics Inc.

AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile

VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635...

AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026

VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Aug. 10, 2026...

AbCellera Reports Q2 2026 Business Results

VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera Reports Q2 2026 Business Results...
Back to Newsroom